. home.aspx



Positive results for Novo’s Xultophy

June 10, 2019 / Anna Smith

Novo Nordisk’s Xultophy (degludec/liraglutide) has been found to significantly delay time-to-treatment intensification when compared to insulin glargine U100 in adults with type II diabetes inadequately controlled on oral treatments. The DUAL VIII trial results were presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco and simultaneously published in The Lancet Diabetes and Endocrinology. The insulin degludec and liraglutide combination helps patients achieve blood glucose targets, with a well-established safety profile. The data showed that over 104 weeks, around 63% of study participants who received Xultophy did not require additional treatment, compared to approximately 34% of those who received insulin glargine U100. With the goal of mirroring clinical practice, participants were followed on average every three months, and met treatment intensification criteria when HbA1c measurements were ≥7% over two consecutive periods. A...